On Oct. 30, 2020, Innovation Pharma and George Mason University jointly announced completion of extensive laboratory testing supporting anti-SARS-CoV-2 activity of Brilacidin, a defensin-mimetic drug candidate being developed as a potential COVID-19 treatment.